In this episode, we speak with Devyn Smith, the CEO of Arbor Biotechnologies, which is an early stage life sciences company pushing the boundaries of biodiscovery.  Arbor has raised over $200 million dollars and is backed by Temasek and other notable investors.

Devyn also serves as Chairman of the Alliance for Regenerative Medicine (ARM) and advises multiple biotech companies. Previously, he was Chief Operations Officer and Head of Strategy at Sigilon Therapeutics, a clinical stage biotechnology company, and before that he was Head of Operations and Strategy, Medicinal Sciences at Pfizer.

Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.

I am your host RJ Lumba.  We hope you enjoy the show.  If you like the episode, click to subscribe.